Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
Florida State University researchers are working on new approaches to deciphering genetic data that may lead to new, more targeted prostate cancer treatments. Prostate cancer, which affects one in ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Hosted on MSN
Clinical trial explores whether a genetic test can improve early detection of prostate cancer
A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...
For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results